Spesolimab-sbzo (Spevigo®)

Covered: Spevigo (spesolimab‑sbzo IV) is authorized only for adult patients (≥18 years) with moderate‑to‑severe generalized pustular psoriasis (GPP) flares that meet specific clinical criteria and is excluded for patients <18, mild flares, maintenance use, or flares that do not meet the required severity/pustulation/BSA or lack dermatologist involvement. Key requirements: initial approval requires documented GPPGA total ≥3 and pustulation subscore ≥2, new/worsening pustules affecting ≥5% BSA, prescription by or consultation with a dermatologist; dosing is a single 900 mg IV (optional second 900 mg at 1 week), maximum two doses per flare, authorization limited to 3 months, and reauthorization requires no more than two doses for the current flare and ≥12 weeks between treatment for new flares.

"Spevigo is indicated for the treatment of generalized pustular psoriasis flares in adults."